Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

被引：1

作者：

Patel, Krish ^{[1
]}

Vose, Julie M. ^{[2
]}

Nasta, Sunita D. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Maddocks, Kami J. ^{[6
]}

Woyach, Jennifer A. ^{[6
]}

Shah, Nirav N. ^{[7
]}

Fakhri, Bita ^{[8
]}

Tessoulin, Benoit ^{[9
]}

Ma, Shuo ^{[10
]}

Jagadeesh, Deepa ^{[11
]}

Lech-Maranda, Ewa ^{[12
]}

Coombs, Catherine C. ^{[13
]}

Patel, Manish ^{[14
]}

Rhodes, Joanna M. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Hoffmann, Marc S. ^{[17
]}

Cheah, Chan Y. ^{[18
,19
]}

Munir, Talha ^{[20
]}

Lewis, David ^{[21
]}

Scarfo, Lydia ^{[22
]}

Eyre, Toby A. ^{[23
]}

Alencar, Alvaro J. ^{[24
]}

Cohen, Jonathon B. ^{[25
]}

Zelenetz, Andrew D. ^{[26
]}

Tsai, Donald E. ^{[27
]}

Li, Mei ^{[28
]}

Bian, Faith ^{[28
]}

Abada, Paolo ^{[27
]}

Zinzani, Pier Luigi ^{[29
]}

机构：

[1] Swedish Canc Inst, Seattle, WA USA

[2] Univ Nebraska Med Ctr, Omaha, NE USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Dana Farber Canc Inst, Chron Lymphocyt Leukemia Ctr, Div Med Oncol, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[7] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[8] Stanford Univ, Sch Med, Stanford, CA USA

[9] Univ Hosp, Dept Hematol, Nantes, France

[10] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA

[11] Inst Hematol & Transfus Med, Warsaw, Poland

[12] Univ Calif Irvine, Irvine, CA USA

[13] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[14] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[15] Fred Hutchinson Canc Ctr, Seattle, WA USA

[16] Univ Kansas, Ctr Canc, Kansas City, KS USA

[17] Linear Clin Res, Nedlands, WA, Australia

[18] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[19] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[20] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England

[21] Univ Vita Salute San Raffaele, Milan, Italy

[22] IRCCS San Raffaele Sci Inst, Milan, Italy

[23] Oxford Univ Hosp NHS Trust, Dept Clin Haematol, Old Rd, Oxford, England

[24] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami Beach, FL USA

[25] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[26] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[27] Loxo Lilly, Indianapolis, IN USA

[28] Eli Lilly & Co, Indianapolis, IN 46285 USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180048

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：9

共 50 条

[31] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
Eyre, Toby
Shah, Nirav N.
Alencar, Alvaro
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal A.
Ghia, Paolo
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 142 - 143
[32] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
BLOOD, 2020, 136
[33] Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, Anthony R.
Shah, Nirav N.
Jurczak, Wojciech
Cheah, Chan Y.
Pagel, John M.
Woyach, Jennifer A.
Fakhri, Bita
Eyre, Toby A.
Lamanna, Nicole
Patel, Manish R.
Alencar, Alvaro
Lech-Maranda, Ewa
Wierda, William G.
Coombs, Catherine C.
Gerson, James N.
Ghia, Paolo
Le Gouill, Steven
Lewis, David John
Sundaram, Suchitra
Cohen, Jonathon B.
Flinn, Ian W.
Tam, Constantine S.
Barve, Minal A.
Kuss, Bryone
Taylor, Justin
Abdel-Wahab, Omar
Schuster, Stephen J.
Palomba, M. Lia
Lewis, Katharine L.
Roeker, Lindsey E.
Davids, Matthew S.
Tan, Xuan Ni
Fenske, Timothy S.
Wallin, Johan
Tsai, Donald E.
Ku, Nora C.
Zhu, Edward
Chen, Jessica
Yin, Ming
Nair, Binoj
Ebata, Kevin
Marella, Narasimha
Brown, Jennifer R.
Wang, Michael
LANCET, 2021, 397 (10277): : 892 - 901
[34] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 13 - 14
[35] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
Cohen, Jonathon B.
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fahkri, Bita
Jurczak, Wojciech
Tan, Xuan N.
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian
Lewis, David J.
Le Gouill, Stephen
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S378 - S379
[36] Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Wang, Michael L.
Brown, Jennifer R.
Patel, Krish
Woyach, Jennifer A.
Wierda, William G.
Ujjani, Chaitra S.
Eyre, Toby A.
Zinzani, Pier Luigi
Alencar, Alvaro J.
Gastinne, Thomas
Ghia, Paolo
Lamanna, Nicole
Hoffmann, Marc
Patel, Manish R.
Flinn, Ian W.
Gerson, James N.
Ma, Shuo
Coombs, Catherine C.
Cheah, Chan Y.
Lech-Maranda, Ewa
Fakhri, Bita
Kim, Won-Seog
Barve, Minal A.
Cohen, Jonathon B.
Jurczak, Wojciech
Munir, Talha
Thompson, Meghan C.
Roeker, Lindsey E.
Bao, Katherine
Cangemi, Nicholas A.
Kherani, Jennifer F.
Walgren, Richard A.
Han, Hongmei
Ruppert, Amy S.
Mato, Anthony R.
BLOOD, 2022, 140 : 4127 - 4132
[37] Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Izutsu, Koji
Ma, Shuo
Flinn, Ian
Alencar, Alvaro J.
Lewis, David
Patel, Krish
Maddocks, Kami
Wang, Yucai
Munir, Talha
Zelenetz, Andrew D.
Balbas, Minna
Tsai, Donald E.
Wang, Chunxiao
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S459 - S459
[38] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN
Munir, Talha
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 110 - 111
[39] Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN Study
Brown, Jennifer
Desikan, Sai Prasad
Nguyen, Bastien
Won, Helen
Tantawy, Shady I.
McNeely, Samuel C.
Marella, Narasimha
Ebata, Kevin
Woyach, Jennifer
Patel, Krish
Tam, Constantine S.
Eyre, Toby A.
Cheah, Chan Y.
Shah, Nirav
Ghia, Paolo
Jurczak, Wojciech
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Mato, Anthony
Gandhi, Varsha
Wierda, William
LEUKEMIA & LYMPHOMA, 2023, 64 : S25 - S26
[40] Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.
Cao, Guoqing
Jin, Zhengming
Li, Yuhua
Zhang, Liling
Shi, Junwei
Jin, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →